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Cystatins are cysteine protease inhibitors that are at the front-line of defense against pathogens that secrete
proteases as virulence factors. In this issue, Vincents et al. (2008) reveal how the bacterial protease IdeS from
Streptococcus pyogenes hijacks normal cystatin C function to convert it into a cofactor that enhances pro-
teolytic destruction of host-defense antibodies.The human pathogen Streptococcus pyo-
genes (group A streptococcus) is a Gram-
positive bacterium that is the etiological
agent of diverse diseases ranging from
scarlet fever to life-threatening conditions
such as necrotizing fascitis. Successful
infection by S. pyogenes depends upon
its ability to counteract the host’s immune
responses. In particular, recognition of
the bacteria by specific IgG antibodies re-
sults in its rapid elimination from human
blood via complement activation and cir-
culating innate immune cells.
Antibodies are therefore critical media-
tors of the humoral immune response that
prime bacterial pathogens for elimination
from the host. In response to these de-
fense mechanisms, S. pyogenes has
evolved multiple virulence determinants
that permit the evasion of antibody-medi-
ated immune responses. For example,
S. pyogenes coats its surface with M-pro-
tein, a cell wall-anchored protein that
binds the Fc region of antibodies, thereby
blocking recognition by immune cells. In
addition, the bacterium secretes the
IgG-inactivating cysteine proteases SpeB
and IdeS (von Pawel-Rammingen and
Bjorck, 2003). Whereas SpeB is ex-
pressed late in infection and has activity
against many substrates, IdeS is pro-
duced early in infection and exhibits
exclusive specificity for the human IgG
subtypes. Although both SpeB and IdeS
cleave IgG at the same site to generate
two stable Fab fragments and one Fc
fragment, the expression pattern and
substrate specificity of IdeS suggest
that it is the major factor that protects
S. pyogenes from immune targeting by
IgG antibodies (von Pawel-Rammingen
and Bjorck, 2003).Consistent with this hypothesis, IdeS
has been shown to reduce Fc-mediated
phagocytic killing and improve survival
of S. pyogenes in human blood (von Pa-
wel-Rammingen et al., 2002; Lei et al.,
2001). Furthermore, patients with S. pyo-
genes infections produce antibodies spe-
cific for IdeS that are capable of neutraliz-
ing its catalytic function (Lei et al., 2001;
Akesson et al., 2006). Consequently,
developing inhibitors of the IgG endopep-
tidase activity of IdeS may have therapeu-
tic potential. A possible mode of inhibiting
IdeS activity was suggested by the recent
X-ray crystal structures of IdeS (Wenig
et al., 2004; Agniswamy et al., 2006),
which revealed that it adopts a canon-
ical papain-like fold despite a lack of
sequence homology with papain-like pro-
teases. This observation suggests that
cystatins, endogenous proteinaceous in-
hibitors that reversibly bind to the active
site cleft of cysteine proteases, might
serve as host defense factors that block
the degradation of IgG by IdeS.
Cystatins have long been recognized as
important mediators of innate immunity
and have been shown to reduce the
growth of a variety of viral, parasitic, and
bacterial pathogens that deploy cysteine
proteases as virulence factors (Dubin,
2005). However, in this issue of Chemistry
& Biology, Vincents et al. (2008) find that
S. pyogenes has devised an elegant solu-
tion to this host defense mechanism by
creating a protease that can convert an
inhibitor into a cofactor that stimulates
rather than reduces its activity. The au-
thors find that although most cystatins
failed to significantly inhibit IgG cleavage
by IdeS, human cystatin C unexpectedly
enhanced IdeS function both in vitro andChemistry & Biology 15, September 22, 200in human samples. This observation ap-
pears to be the first example of a protease
inhibitor dually functioning as an inhibitor
and activator and represents yet another
mechanism by which bacterial pathogens
co-opt host cell proteins to enhance their
virulence.
Although determining the precise
mechanism by which cystatin C promotes
IdeS activity requires further experimen-
tation, Vincents et al. (2008) present
evidence indicating that cystatin C alters
the conformational state and/or stoichi-
ometry of IdeS. The cofactor effect of cys-
tatin C was observed primarily at low con-
centrations of IdeS, and SPR experiments
suggest that cystatin C improves IdeS di-
merization, a process that has previously
been reported to enhance protease activ-
ity (Agniswamy et al., 2006). Based on
these observations, the authors propose
a model in which binding of IdeS to cysta-
tin C serves as a mechanism to compen-
sate for the reduction in IdeS activity
that occurs upon radial diffusion of the
protease into bodily fluids (Figure 1). Stim-
ulation of IdeS activity by cystatin C at
these remote sites releases Fc fragments
that could prime circulating neutrophils at
a distance from S. pyogenes (So¨derberg
and von Pawel-Rammingen, 2008).
The identification of mutations in IdeS
that reduce its interaction with cystatin C
but that fail to disrupt IdeS catalytic func-
tion might allow this model to be tested
in vivo. It would also be interesting to
examine whether cystatin C binding to
IdeS counteracts the neutralizing effect
of antibodies specific for IdeS. Regard-
less, delineating the interfaces on both
IdeS and cystatin C that mediate these
interactions will undoubtedly provide8 ª2008 Elsevier Ltd All rights reserved 879
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both as a protease inhibitor and cofactor,
and how IdeS functions as an endopepti-
dase specific for IgG. Intriguingly, both
IdeS and cystatin C have been demon-
strated to have multiple protein binding
sites. In addition to recruiting cystatin C,
IdeS binds IgG through an exosite inter-
action (Vincents et al., 2004) and integrins
through its RGD motif (Lei et al., 2001).
Similarly, cystatin C has been shown to
form a ternary complex with papain and
legumain; cystatin C binding to papain
does not affect its interaction with legu-
main (Alvarez-Fernandez et al., 1999).
Since IdeS has proven resistant to most
small molecule inhibitors that target its
active site, the findings of Vincents et al.
Figure 1. IdeS Inactivates IgG Antibodies in Mutiple Cellular Contexts
(A) On the surface of S. pyogenes, IdeS cleaves IgG bound to cell wall-anchored M and M-like protein
through its Fc region, releasing unbound Fab fragments from the bacterial surface.
(B) IdeS inactivates opsonizing IgG antibodies bound to the bacterial surface proteins by cleaving the
hinge region of IgG subtypes. As IdeS diffuses away fromS. pyogenes, the dilution effect results in lowered
IdeS activity, since IdeS functions optimally as a dimer and thus is concentration dependent.
(C) At remote sites, IdeS binding to cystatin C, the most abundant cystatin in the human body, induces
a conformational change that enhances IdeS activity, allowing IdeS to cleave circulating IgG more
efficiently. Inactivation of circulating IgG by IdeS may stimulate immune responses at a distance from
S. pyogenes, since released Fc fragments have been shown to prime circulating neutrophils (So¨derberg
and von Pawel-Rammingen, 2008).880 Chemistry & Biology 15, September 22, 2008 ª2008 Elsevier Ltd All rights reserved(2008) suggest that inhibitors that disrupt
the interaction of IdeS with cystatin C or
with itself might be a more effective thera-
peutic strategy. While it is still not clear
whether cystatins may generally act as
cofactors for other protease targets, this
unexpected discovery should prompt
closer scrutiny of the relationship be-
tween proteinaceous protease inhibitors
and their target proteases.
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